drugset / Trial / NCT03903458
Tinostamustine and Nivolumab in Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This trial is a first-in-human drug combination with the first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule Tinostamustine (EDO-S101) and the anti-PD-1 monoclonal antibody Nivolumab in patients with refractory, locally advanced or metastatic melanoma.
Timeline
- Start
- 2019-03-07
- Primary completion
- 2021-12-15
- Completion
- 2024-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tinostamustine | Other / unclassified | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |